Teva just went through a horrible year, today reporting a $17.5 billion operating loss in 2017, but executives said things will get worse before they get better for its generics business, even as it faces a potential delay for its new migraine medication.Original Article
Teva faces unexpected delay for its migraine drug candidate even as generics pressures worsen
